Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | FPI-2053 + FPI-2068 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FPI-2053 | FPI 2053|FPI2053 | EGFR Antibody 56 MET Antibody 29 | FPI-2053 is a bispecific antibody targeting EGFR and MET (Mol Cancer Ther (2023) 22 (12_Supplement): A146). | |
FPI-2068 | FPI2068|FPI 2068|[225Ac]-FPI-2068|225Ac-FPI-2068 | EGFR Antibody 56 MET Antibody 29 | FPI-2068 is a radioconjugate comprising a bispecific antibody that targets EGFR and MET linked to the radionuclide Actinium-225, which delivers radiation to tumor cells and potentially inhibits tumor growth (Mol Cancer Ther (2023) 22 (12_Supplement): A146). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06147037 | Phase I | FPI-2053 + FPI-2068 | A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours | Recruiting | USA | CAN | 0 |